Latest Biologic Stories
DALLAS, March 19, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "PharmaPoint: Rheumatoid Arthritis - US and 5EU Drug Forecast and Market Analysis to 2023" report provides
SOUTH SAN FRANCISCO, Calif., March 19, 2015 /PRNewswire/ -- CytomX, a biotechnology company developing Probody(TM) therapeutics for the treatment of cancer, today announced the appointment of
SEATTLE and BERKELEY, Calif.
In the wake of the Food and Drug Administration’s first approval for a biosimilar product, pharma industry experts offer advice on how payers can prepare for this new class of drugs in the March
Pivotal Results Comparing Brodalumab With Stelara® (Ustekinumab) and Placebo to be Presented in Late-Breaking Session THOUSAND OAKS, Calif., March 17, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
CE Class Focuses on Fundamentals of Biosimilars EAST ELMHURST, N.Y., March 16, 2015 /PRNewswire/ -- With the U.S.
If authorized, SB2 will be marketed in Europe by Biogen Idec INCHEON, South Korea, March 13, 2015 /PRNewswire/ -- Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization
According to the new report from BCC Research, the global biosimilars market was valued at $1.8 billion in 2013 and nearly $2.0 billion in 2014.
SAN DIEGO, March 10, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.